Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Blood (2020) 136 (22): 2513–2523.

https://doi.org/10.1182/blood.2020007522

Published: 2020

Includes: Supplemental data

Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Blood (2017) 130 (Supplement 1): 4533.

https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533

Published: 2017

Journal Articles

5-Hydroxymethylcytosine of Circulating Cell-Free DNA in Plasma: A Novel Non-Invasive Marker for Progression and Prognosis in Multiple Myeloma

Brian C.-H. Chiu, PhD, Qiancheng You, BS, Zhou Zhang, PhD, Elizabeth Stepniak, MPH, Xu Zhang, PhD, Meytal Chernoff, BS, Todd M. Zimmerman, Chuan He, PhD, Wei Zhang, PhD

Blood (2017) 130 (Supplement 1): 4336.

https://doi.org/10.1182/blood.V130.Suppl_1.4336.4336

Published: 2017

Journal Articles

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Paul G. Richardson, Todd M. Zimmerman, Craig C. Hofmeister, Moshe Talpaz, Asher A. Chanan-Khan, Jonathan L. Kaufman, Jacob P. Laubach, Dharminder Chauhan, Andrzej J. Jakubowiak, Steven Reich, Mohit Trikha, Kenneth C. Anderson

Blood (2016) 127 (22): 2693–2700.

https://doi.org/10.1182/blood-2015-12-686378

Published: 2016

Journal Articles

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Shaji K. Kumar, William I. Bensinger, Todd M. Zimmerman, Craig B. Reeder, James R. Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Jiang Yu, Yaping Shou, Ruben Niesvizky

Blood (2014) 124 (7): 1047–1055.

https://doi.org/10.1182/blood-2014-01-548941

Published: 2014

Includes: Supplemental data

Journal Articles

Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans

Blood (2013) 122 (21): 1872.

https://doi.org/10.1182/blood.V122.21.1872.1872

Published: 2013

Journal Articles

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Erik H van Beers, PhD, Martin H. Van Vliet, PhD, Kenneth C. Anderson, MD, Ajai Chari, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Shaji K Kumar, MD, Daniel Lebovic, MD, Joan Levy, PhD, Sagar Lonial, M.D., Donna E Reece, MD, FRCPC, Paul G. Richardson, MD, David S Siegel, MD, PhD, Keith Stewart, MBA, MB, CHB, Suzanne Trudel, MD, MSC, FRCPC, Ravi Vij, MD, Todd M. Zimmerman, MD, Rafael Fonseca, M.D.

Blood (2013) 122 (21): 1854.

https://doi.org/10.1182/blood.V122.21.1854.1854

Published: 2013

Journal Articles

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Beverly Harrison, Kenneth C. Anderson, MD, Noopur Raje, MD, Paul Richardson, MD, Diane Warren, Ajai Chari, MD, Sundar Jagannath, MD, Lisa La, Jesus Berdeja, MD, Meredith Zimlich, Joseph W. Fay, MD, Sheila Powell, RN, Craig C Hofmeister, MD, Nita Williams, BS, Andrzej J. Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Kathryn McDonnell, Amrita Y. Krishnan, MD, Lupe Duarte, CCRC, Shaji K Kumar, MD, Ann Birgin, CRA, Sagar Lonial, M.D., Kenisha Baron, Thomas Martin, MD, Jeffrey L Wolf, MD, Geraldine Pelle-Day, Ph.D., Glenna Auerback, Gregory Orloff, MD, Nikki Hodge, Donna E Reece, MD, FRCPC, Suzanne Trudel, MD, Engin Gul, HonBSc, Vivek Roy, M.D., Michele Maharaj, RN, David S. Siegel, MD, PhD, Adolfo Aleman, A. Keith Stewart, Rachel Hagerty, Moshe Talpaz, MD, Roxane Collins, Ravi Vij, MD, Mark A. Fiala, BS, CCRP, Jeffrey Zonder, M.D., Silva Pregja, Sharon Goldberg, Joan Levy, PhD, Karen Dietz, Walter Capone, Daniel Auclair, PhD, Anne Quinn Young, Kathy Giusti, MBA

Blood (2013) 122 (21): 5388.

https://doi.org/10.1182/blood.V122.21.5388.5388

Published: 2013

Journal Articles

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Kevin R. Kelly, MD, PhD, Asher Chanan-Khan, MD, George Somlo, MD, Leonard T Heffner, MD, David S Siegel, MD, PhD., Todd M Zimmerman, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Sagar Lonial, M.D., Vivek Roy, M.D., Markus Ruehle, MD, Shailesh Chavan, MD, Pankaj Patel, PhD, Markus Rothenburger, MD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson

Blood (2013) 122 (21): 758.

https://doi.org/10.1182/blood.V122.21.758.758

Published: 2013

Journal Articles

Pilot Study Of Regulatory T Cell Depletion In The Setting Of Autologous Stem Cell Transplantation For Multiple Myeloma

Gottfried von Keudell, MD, PhD, Cara A Rosenbaum, MD, Todd M. Zimmerman, MD, Michael Bishop, MD, Koen van Besien, MD, Rebecca Malloy, RN, BSN, Amittha Wickrema, PhD, Andrzej Jakubowiak, MD, PhD, Justin Paul Kline, MD

Blood (2013) 122 (21): 4607.

https://doi.org/10.1182/blood.V122.21.4607.4607

Published: 2013

Journal Articles

Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles

Blood (2013) 122 (21): 532.

https://doi.org/10.1182/blood.V122.21.532.532

Published: 2013

Journal Articles

Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.

Shaji K. Kumar, MD, Amrita Krishnan, MD, Vivek Roy, M.D., Todd M Zimmerman, MD, Morie Abraham A Gertz, MD, Keith E. Stockerl-Goldstein, MD, Francis K Buadi, M.D., Cara Rosenbaum, MD, Ann Birgin, CRA, Mark Fiala, BS, CCRP, Valeria Jiminez, Michele Maharaj, RN, Michael N. Needle, MD, Ravi Vij, MD

Blood (2012) 120 (21): 2965.

https://doi.org/10.1182/blood.V120.21.2965.2965

Published: 2012

Journal Articles

QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Sheeba K. Thomas, MD, Alexander Suvorov, MD, Lucien Noens, MD, PhD, Oleg Rukavitsin, MD, Joseph Fay, MD, Ka Lung Wu, MD, PhD, Todd M Zimmerman, MD, Helgi van de Velde, MD, PhD, Rajesh Bandekar, PhD, Thomas A Puchalski, PharmD, Ming Qi, MD, PhD, Clarissa Uhlar, PhD, Olga S Samoilova, MD

Blood (2012) 120 (21): 2972.

https://doi.org/10.1182/blood.V120.21.2972.2972

Published: 2012

Journal Articles

Explaining the Excess Risk of Multiple Myeloma in African-Americans

Blood (2012) 120 (21): 4002.

https://doi.org/10.1182/blood.V120.21.4002.4002

Published: 2012

Journal Articles

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Leonard T Heffner, MD, Sundar Jagannath, MD, Todd M Zimmerman, MD, Kelvin P Lee, MD, Jacalyn Rosenblatt, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Niklas Czeloth, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2012) 120 (21): 4042.

https://doi.org/10.1182/blood.V120.21.4042.4042

Published: 2012

Journal Articles

Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

Shaji Kumar, MD, William I Bensinger, MD, Craig B. Reeder, MD, Todd M. Zimmerman, MD, James R. Berenson, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Ai-Min Hui, MD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 816.

https://doi.org/10.1182/blood.V118.21.816.816

Published: 2011

Journal Articles

The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development

Blood (2011) 118 (21): 1024.

https://doi.org/10.1182/blood.V118.21.1024.1024

Published: 2011

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher Chanan-Khan, MD, Leonard T. Heffner, MD, David Avigan, MD, Todd M. Zimmerman, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Andre Engling, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2011) 118 (21): 305.

https://doi.org/10.1182/blood.V118.21.305.305

Published: 2011

Journal Articles

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Paul G. Richardson, MD, Andrew Spencer, MD, Paul Cannell, MBBS, FRCPA, FRACP, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Laurence Catley, MBBS, FRCPA, FRACP, Craig Underhill, MBBS, FRACP, Todd M. Zimmerman, MD, Craig C. Hofmeister, MD, Andrzej J Jakubowiak, MD, PhD, Jacob P. Laubach, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Ana Lay, Sandra Wear, RN, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Steve Reich, MD, Matthew A. Spear, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 302.

https://doi.org/10.1182/blood.V118.21.302.302

Published: 2011

Journal Articles

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Blood (2011) 118 (3): 535–543.

https://doi.org/10.1182/blood-2011-02-334755

Published: 2011

NARROW

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

5-Hydroxymethylcytosine of Circulating Cell-Free DNA in Plasma: A Novel Non-Invasive Marker for Progression and Prognosis in Multiple Myeloma

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma

Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients

Pilot Study Of Regulatory T Cell Depletion In The Setting Of Autologous Stem Cell Transplantation For Multiple Myeloma

Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles

Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of Bendamustine in Combination with Lenalidomide and Dexamethasone (BRD) in Patients with Relapsed Multiple Myeloma: A Multiple Myeloma Research Consortium Study.

QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Explaining the Excess Risk of Multiple Myeloma in African-Americans

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study

The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only